The common conclusion, that these peptides quit after a certain age, is wrong, but it is circling something real. Someone runs CJC-1295, then runs Tesamorelin, feels almost nothing, and decides the compound failed. In most cases the compound did exactly what it was built to do. It sent the signal. The part that got quieter is the response, and that has nothing to do with the quality of the peptide and everything to do with what age does to the system underneath it.

Understanding why the response gets quieter is the whole difference between thinking a compound failed and knowing what you are actually working with. This piece breaks down what each of these two compounds does, what genuinely declines with age, which is not what most people assume, and the one blood marker that tells you where your own output actually sits before you spend another cycle guessing. Everything here is for educational and research purposes only.

Both compounds belong to the same family. They are GHRH analogs, which means they are copies of growth hormone releasing hormone, the natural signal your body sends when it wants growth hormone produced. That signal normally travels to the cells in the pituitary that manufacture and release growth hormone and tells them to get ready and let a pulse out. CJC-1295 and Tesamorelin both imitate that signal. So at the mechanism level they are doing the same job. Where they differ is not what they do, but how long they last and how they shape the release.

Tesamorelin is a stabilized copy of the full-length human version of that signal, a chain of 44 amino acids. It is the only compound in this pair that is FDA approved, cleared specifically to reduce visceral fat, the deep fat that sits around your organs, in one medical population, and it carries the strongest clinical evidence of the two for moving that fat. It clears the body quickly, with a half life measured in minutes rather than days, which is why it is typically used daily and why it tends to preserve the natural on-and-off pulsing pattern your body already runs.

CJC-1295 is a shortened, modified version of the same signal, and here one detail matters more than any other, because it changes the compound completely. CJC-1295 comes in two forms. The version with DAC, which stands for drug affinity complex, carries a tag that binds to albumin, a carrier protein in your blood, and that tag stretches its half life out to roughly six to eight days. That long tail produces a steady, sustained rise in growth hormone and IGF-1 rather than clean separate pulses, and it is usually dosed about once a week. The version without DAC, often labeled modified GRF 1-29 or CJC-1295 no-DAC, clears in minutes like Tesamorelin and keeps the natural pulsing pattern intact. Two products share the same name and behave differently, so knowing which one is in a vial is not a small detail, it is the whole picture.

The reason all of this matters for the after-40 question is simple. Every one of these is the same kind of signal doing the same job, which is priming a growth hormone pulse. Their differences are about timing and rhythm, not about which one can beat age. None of them can manufacture capacity that is not there. That is the part the age question actually turns on, so that is what the rest of this covers.

Most people get this part backwards. The common assumption is that after 40 your body simply makes less growth hormone, as if the machinery wore out. That is not what happens. Your pituitary does not release growth hormone in a steady stream. It releases it in pulses, short bursts, and the biggest ones fire during deep sleep. What declines with age is not the ability to produce growth hormone. It is the size and the frequency of those bursts.

This pattern has a name. It is called somatopause, the gradual decline in growth hormone output that begins in your 20s and continues through every decade after. Research, including work published in endocrinology journals, points to an average decline in the range of 14 percent per decade. Added up over time that is not a small number. Someone at 48 may be working with a fraction of the output he had at 25, and none of it happened fast enough to notice. There was no morning it dropped. It shrank a little each year while everything else stayed the same.

This is why a GHRH analog can feel flat. The cells that actually make and release growth hormone are called somatotropes, and they are what the signal talks to. When CJC-1295 or Tesamorelin arrives, the message lands exactly the way it is supposed to. The question is what those cells can produce when it does. Think of it as the difference between the message and the capacity to answer it. A GHRH compound is a stronger message, but it cannot build capacity that is not there. When those cells have less to give, they still answer, just within their range, and the pulse that follows is smaller than the identical signal would produce in a 24 year old. No dose of a GHRH analog changes that, because the limit is on the answering side, not the signal side.

There is a second thing working against you, and this one gets overlooked. Your body runs a braking signal called somatostatin, the hormone that tells the pituitary to slow growth hormone production whenever output starts to rise. That brake is always engaged to some degree, because it is how the body protects its own balance. Research suggests that with age the brake grows stronger relative to the signal that tells the pituitary to release. So you are not only working with fewer cells that each have less to give. You are working with cells that have less to give while the brake is being held down harder than it used to be. Two separate age effects, stacking on top of each other.

On top of that there is a feedback loop that explains something people find confusing. When a pulse does fire, the liver responds by producing IGF-1, which stands for insulin-like growth factor 1 and is the downstream messenger that carries out much of what growth hormone is credited with. Here is the catch. Raising IGF-1 calls for more somatostatin, and more somatostatin means more braking. The system pushes back against being driven harder. That is why stacking more stimulus on more stimulus does not produce a proportionally bigger result, and it is also why running two GHRH analogs together, two compounds from the same class competing for the same receptor, tends to produce redundancy and receptor saturation rather than a bigger pulse. The body is built to resist being forced past its own setpoint.

This is the part that matters more than which of the two compounds someone picked. Releasing a growth hormone pulse takes two separate signals, not one. The first tells the pituitary to get ready and load up a pulse, and that is exactly what CJC-1295 and Tesamorelin do. The second pulls the trigger and lets the pulse out. That second signal is a GHRP, which stands for growth hormone releasing peptide, and ipamorelin is the one most researchers use. A GHRP does two things a GHRH analog does not. It fires the pulse, and it briefly quiets the somatostatin brake at the same time. One signal gets the pulse ready. The other releases it and eases the brake. It takes both to get a full release.

So someone running CJC-1295 or Tesamorelin on its own got the pulse ready and never fully pulled the trigger. That is not a fault in either compound. It is half of a two-part system being asked to do a whole job. This is also why pairing a GHRH analog with a GHRP has real mechanistic logic behind it, while pairing two GHRH analogs does not. The two halves are different signals that complement each other. Two of the same half just compete for the same receptor. Adding a GHRP will not hand you back the capacity that age took, but it makes far better use of whatever capacity you have left, which for a lot of people is the actual gap between a flat result and a real one. There is a longer breakdown of that pairing in why the CJC-1295 and ipamorelin stack works.

This is also why two men the same age can run the identical protocol and report completely different outcomes. That 14 percent per decade is an average, not a schedule, and the individual variation around it is large. Two men at 45 can genuinely be in different places, and neither of them knows where he actually stands, because almost nobody measures the one number that would tell him.

IGF-1 is produced in proportion to your growth hormone pulse, which makes it a practical readout of what your system is actually putting out. It is a standard blood test, nothing exotic. Most men over 40 have had testosterone checked at least once and have never had IGF-1 measured a single time. That is the real problem sitting underneath the after-40 question. Running a growth hormone secretagogue, which just means a compound that prompts your body to release its own growth hormone, without measuring IGF-1 leaves you with no baseline and no way to read the response. You are left judging the compound by how you feel, and how you feel is the least reliable instrument you own. It moves with sleep, stress, water, and mood, none of which are the compound. If you want a plain comparison of what each compound in this space does at the level of that readout, there is one in Tesamorelin vs CJC-1295 vs IGF-1 LR3.

When you put all of it together, what you get out of a growth hormone protocol comes down to three things, and they stack in this order. First is capacity, which is simply how much your somatotropes can produce, and it is where your age sits. You cannot signal your way around it and you cannot feel it, which is why testing IGF-1 is how you get a real read on where you stand. Second is the environment at the moment you signal, meaning sleep quality, insulin from recent meals, stress, and your body composition, all of which research suggests can blunt pulse height on their own regardless of age. Third and last is the protocol itself, the compound and whether both halves of the signal are present, meaning a GHRH analog like CJC-1295 or Tesamorelin paired with a GHRP like ipamorelin.

The question that decides whether any of this is worth continuing is not which compound to run next. It is whether you know where your own output actually sits, and right now most people do not, because it was never measured. If you are considering a growth hormone secretagogue, the first move is to get IGF-1 tested and find out which version of this you are dealing with. If it comes back reasonable for your age, the flat result was most likely the environment or the protocol design, often the missing GHRP. If it comes back genuinely low, that is a different conversation, and it belongs with your provider rather than a comment section. Either way, you stop guessing. Research suggests that an outside source of growth hormone is something some people weigh after a certain age, but that is a decision to work through with a provider, not a protocol to copy. The baseline comes first, and the baseline is IGF-1.

Project Theo is an educational research resource. Everything here is for educational and research purposes only and is not medical advice. Nothing on this page is a recommendation to obtain, possess, or administer any compound. Speak with a licensed provider before making any decision about your health.